Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
about
Haloperidol dose for the acute phase of schizophreniaHaloperidol versus placebo for schizophreniaHaloperidol versus placebo for schizophreniaSertindole for schizophreniaPharmacologic treatment of schizophreniaNovel antipsychotics: issues and controversies. Typicality of atypical antipsychotics.Haloperidol dose for the acute phase of schizophrenia.Sertindole for schizophrenia.Haloperidol versus placebo for schizophrenia.Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literatureThe use of atypical antipsychotics in the management of schizophrenia.Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part IIDetermining the optimal dose of haloperidol in first-episode psychosis.Emerging treatments in the management of schizophrenia - focus on sertindoleZiprasidone and the corrected QT interval: a comprehensive summary of clinical data.Drug safety and efficacy evaluation of sertindole for schizophrenia.Dopamine D2 occupancy as a biomarker for antipsychotics: quantifying the relationship with efficacy and extrapyramidal symptoms.Unanswered questions in schizophrenia clinical trialsDopamine and serotonin receptor binding and antipsychotic efficacy.World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance.The European post-marketing observational sertindole study: an investigation of the safety of antipsychotic drug treatment.Past and present progress in the pharmacologic treatment of schizophrenia.How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials.Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms.Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis.Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences.State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.Actigraphic measurement of the effects of single-dose haloperidol and olanzapine on spontaneous motor activity in normal subjects.Weight gain profiles of new anti-psychotics: public health consequences.Understanding antipsychotic "atypicality": a clinical and pharmacological moving targetTreatments for chronic psychosis.Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent.Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations.Olanzapine: a 5-year perspective.Sertindole: efficacy and safety in schizophrenia.Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response.Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.Second-generation antipsychotics for schizophrenia: can we resolve the conflict?Review of the efficacy of placebo in comparative clinical trials between typical and atypical antipsychotics.Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
P2860
Q24200200-C65F2D0B-9E5F-47CF-97BD-E36E8082022DQ24202457-04F1EE4A-2927-4D76-8EA0-94A07017A3B8Q24243823-2FC08D93-3790-402B-9D25-99C8CBDA02E0Q24246531-3DC0DC06-CD09-4C3D-8EF7-8273A4F8B27AQ24604457-25730912-3418-45DE-8E81-FC88F9F8EBFBQ30501297-68F59E3A-8FD6-4167-AA2B-9D757E3113A0Q30838771-EDF62BF9-59BD-4257-8F7B-8C000E366F41Q30868048-01727515-81A0-4B31-BED5-0172FEB3261DQ30992683-365169C3-7854-42A0-A97A-7A2CC389DB5AQ31147797-D9135354-5029-4F8D-80C4-243F6F7E6914Q33540449-D4285F9B-3789-4745-8266-6574A09E7007Q33612521-91146484-9571-443E-B774-B344025520D9Q34107268-5D7FCB73-619F-4B76-9D3A-B440B483FDCCQ34129334-57990CCA-84AD-4050-B11D-5B92121AB9AFQ34209287-2198EC04-3A51-4376-A822-A90CD23DC4E0Q34300628-627D1296-B2AD-415A-AA13-34A6A60DCF28Q34544566-EFCF8F99-0D48-4C3A-ACBF-5A70767DEACBQ34587166-83B4CB37-019D-4794-8C9A-24882531B8D5Q34605995-0F940549-DE78-416F-AA89-8DD0DB19B0D3Q34640811-97656411-7E15-49EF-94DC-3A24684CCCB8Q34658561-F85BED79-E874-4B48-B84B-4A1A1E9C8EBFQ34726953-939D40F8-CCE0-4398-8252-567D742D1ED4Q34733976-11D26664-52B9-4022-BC0C-7EBBA451197FQ35009210-E44A4772-89D9-4AA0-ABC3-82926BD48C42Q35065378-38DEED97-A8A2-464E-A027-2037CE201A34Q35073807-C27413F0-075B-4EFA-99D1-414623FAAA22Q35073834-856AE2E9-69CD-47AC-95F4-8CC84D736632Q35162561-D962E18C-589A-4762-932A-126E1FBCEA40Q35198895-68E2DC4D-7862-49A4-A002-0CDF64198A30Q35200831-D137D01A-0A0E-4CA2-8E4C-8AC00750FD0CQ35236418-13E09ECE-A321-41BA-A693-6A6A698FDA58Q35892164-0E75652D-D0EE-4B26-92CA-081C6C665864Q36414518-3FF94882-A1C1-41B7-8F56-942C7E4EDA7DQ36511290-D0937597-8F38-4B61-8179-A0ABFD7A6FADQ36573915-3476E04D-E7D0-455B-8CD1-4FF3A92FADF0Q36804367-B7DC4CFC-92FA-4364-92B4-67D2AFDD7E5CQ37111491-46D68CFA-7524-42BD-B01D-34D960A668B5Q37428125-7CADB927-E501-4E6E-9D04-C6CB760093F8Q37511776-A44A5EBA-4468-49A8-B3B5-5ABBC8412C61Q37532575-0C59E37D-4F3C-4E0A-B012-8C07AE08F2C7
P2860
Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Controlled, dose-response stud ...... renia. Sertindole Study Group.
@en
type
label
Controlled, dose-response stud ...... renia. Sertindole Study Group.
@en
prefLabel
Controlled, dose-response stud ...... renia. Sertindole Study Group.
@en
P2093
P356
P1476
Controlled, dose-response stud ...... renia. Sertindole Study Group.
@en
P2093
Kashkin KB
Tamminga CA
Wozniak PJ
Zimbroff DL
P304
P356
10.1176/AJP.154.6.782
P407
P577
1997-06-01T00:00:00Z